You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
廣生堂(300436.SZ):乙肝治療全球創新藥HBsAg抑制劑GST-HG131臨牀試驗申請獲受理
格隆匯 12-10 16:26

格隆匯12月10日丨廣生堂(300436.SZ)公佈,公司歷經四年完成了GST-HG131申報臨牀試驗所需的全部數據和資料,在獲得pre-IND meeting預核准後,於2019年12月10日收到國家藥品監督管理局下發的《受理通知書》,乙肝治療全球創新藥乙肝表面抗原(HBsAg)抑制劑GST-HG131臨牀試驗申請獲得受理,受理號:CXHL1900412國、CXHL1900413國、CXHL1900414國,註冊分類:化學藥品1類。

公司擁有全球知識產權的乙肝治療全球創新藥GST-HG131,屬First-in-Class全球領先項目,有機會成為全球首個上市的乙肝HBsAg抑制劑創新藥,能夠誘導HBV-RNA降解,快速大幅降低HBsAg水平,且具有良好的安全性,是廣生堂乙肝功能性治癒“登峯計劃”重要組合方案之一。GST-HG131核心化合物已申請PCT國際專利,其中國專利已獲得授權。

廣生堂從成立之初就懷揣着乙肝臨牀治癒的夢想,繼乙肝治療核苷(酸)類系列基石用藥恩替卡韋、替諾福韋等通過一致性評價及乙肝核心蛋白抑制劑GST-HG141獲批臨牀後,此次GST-HG131的臨牀申報受理標誌着廣生堂乙肝功能性治癒“登峯計劃”又向前邁出了重要一步,我們將砥礪前行,科學臨牀,挑戰夢想。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account